ANO7 is associated with aggressive prostate cancer

PRACTICAL Consortium

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prostate cancer is one of the most common and heritable human cancers. Our aim was to find germline biomarkers that can predict disease outcome. We previously detected predisposing signals at 2q37, the location of the prostate specific ANO7 gene. To investigate, in detail, the associations between the ANO7 gene and PrCa risk and disease aggressiveness, ANO7 was sequenced in castration resistant tumors together with samples from unselected PrCa patients and unaffected males. Two pathogenic variants were discovered and genotyped in 1769 patients and 1711 unaffected males. Expression of ANO7 vs. PrCa aggressiveness was investigated. Different databases along with Swedish and Norwegian cohorts were used for validation. Case–control and aggressive vs. nonaggressive association analyses were performed against risk and/or cancer aggressiveness. The ANO7 mRNA level and patient survival were analyzed using expression data from databases. Variant rs77559646 showed both risk (OR 1.40; p = 0.009, 95% CI 1.09–1.78) and association with aggressive PrCa (Genotype test p = 0.04). It was found to be an eQTL for ANO7 (Linear model p-values for Finnish patients p = 0.009; Camcap prostate tumor p = 2.53E-06; Stockholm prostate tumor cohort p = 1.53E-13). rs148609049 was not associated with risk, but was related to shorter survival (HR 1.56; 95% CI 1.03–2.36). High ANO7 expression was independently linked to poor survival (HR 18.4; 95% CI 1.43–237). ANO7 genotypes correlate with expression and biochemical relapse, suggesting that ANO7 is a potential PrCa susceptibility gene and that its elevated expression correlates with disease severity and outcome.

Original languageEnglish
JournalInternational Journal of Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Prostatic Neoplasms
Prostate
Neoplasms
Survival
Genotype
Databases
Genes
Castration
Linear Models
Biomarkers
Recurrence
Messenger RNA

Keywords

  • ANO7
  • CRPC
  • expression
  • prostate cancer
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

ANO7 is associated with aggressive prostate cancer. / PRACTICAL Consortium.

In: International Journal of Cancer, 01.01.2018.

Research output: Contribution to journalArticle

@article{07e8952aa03e45809f3ccf9cf01cf4c6,
title = "ANO7 is associated with aggressive prostate cancer",
abstract = "Prostate cancer is one of the most common and heritable human cancers. Our aim was to find germline biomarkers that can predict disease outcome. We previously detected predisposing signals at 2q37, the location of the prostate specific ANO7 gene. To investigate, in detail, the associations between the ANO7 gene and PrCa risk and disease aggressiveness, ANO7 was sequenced in castration resistant tumors together with samples from unselected PrCa patients and unaffected males. Two pathogenic variants were discovered and genotyped in 1769 patients and 1711 unaffected males. Expression of ANO7 vs. PrCa aggressiveness was investigated. Different databases along with Swedish and Norwegian cohorts were used for validation. Case–control and aggressive vs. nonaggressive association analyses were performed against risk and/or cancer aggressiveness. The ANO7 mRNA level and patient survival were analyzed using expression data from databases. Variant rs77559646 showed both risk (OR 1.40; p = 0.009, 95{\%} CI 1.09–1.78) and association with aggressive PrCa (Genotype test p = 0.04). It was found to be an eQTL for ANO7 (Linear model p-values for Finnish patients p = 0.009; Camcap prostate tumor p = 2.53E-06; Stockholm prostate tumor cohort p = 1.53E-13). rs148609049 was not associated with risk, but was related to shorter survival (HR 1.56; 95{\%} CI 1.03–2.36). High ANO7 expression was independently linked to poor survival (HR 18.4; 95{\%} CI 1.43–237). ANO7 genotypes correlate with expression and biochemical relapse, suggesting that ANO7 is a potential PrCa susceptibility gene and that its elevated expression correlates with disease severity and outcome.",
keywords = "ANO7, CRPC, expression, prostate cancer, survival",
author = "{PRACTICAL Consortium} and Elina Kaikkonen and Tommi Rantapero and Qin Zhang and Pekka Taimen and Virpi Laitinen and Markku Kallajoki and Dhanaprakash Jambulingam and Otto Ettala and Juha Knaapila and Bostr{\"o}m, {Peter J.} and Gudrun Wahlstr{\"o}m and C. Sipeky and Pursiheimo, {Juha Pekka} and Teuvo Tammela and Kellokumpu-Lehtinen, {Pirkko Liisa} and Vidal Fey and Lovise Maehle and Fredrik Wiklund and Wei, {Gong Hong} and Johanna Schleutker",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ijc.31746",
language = "English",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - ANO7 is associated with aggressive prostate cancer

AU - PRACTICAL Consortium

AU - Kaikkonen, Elina

AU - Rantapero, Tommi

AU - Zhang, Qin

AU - Taimen, Pekka

AU - Laitinen, Virpi

AU - Kallajoki, Markku

AU - Jambulingam, Dhanaprakash

AU - Ettala, Otto

AU - Knaapila, Juha

AU - Boström, Peter J.

AU - Wahlström, Gudrun

AU - Sipeky, C.

AU - Pursiheimo, Juha Pekka

AU - Tammela, Teuvo

AU - Kellokumpu-Lehtinen, Pirkko Liisa

AU - Fey, Vidal

AU - Maehle, Lovise

AU - Wiklund, Fredrik

AU - Wei, Gong Hong

AU - Schleutker, Johanna

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Prostate cancer is one of the most common and heritable human cancers. Our aim was to find germline biomarkers that can predict disease outcome. We previously detected predisposing signals at 2q37, the location of the prostate specific ANO7 gene. To investigate, in detail, the associations between the ANO7 gene and PrCa risk and disease aggressiveness, ANO7 was sequenced in castration resistant tumors together with samples from unselected PrCa patients and unaffected males. Two pathogenic variants were discovered and genotyped in 1769 patients and 1711 unaffected males. Expression of ANO7 vs. PrCa aggressiveness was investigated. Different databases along with Swedish and Norwegian cohorts were used for validation. Case–control and aggressive vs. nonaggressive association analyses were performed against risk and/or cancer aggressiveness. The ANO7 mRNA level and patient survival were analyzed using expression data from databases. Variant rs77559646 showed both risk (OR 1.40; p = 0.009, 95% CI 1.09–1.78) and association with aggressive PrCa (Genotype test p = 0.04). It was found to be an eQTL for ANO7 (Linear model p-values for Finnish patients p = 0.009; Camcap prostate tumor p = 2.53E-06; Stockholm prostate tumor cohort p = 1.53E-13). rs148609049 was not associated with risk, but was related to shorter survival (HR 1.56; 95% CI 1.03–2.36). High ANO7 expression was independently linked to poor survival (HR 18.4; 95% CI 1.43–237). ANO7 genotypes correlate with expression and biochemical relapse, suggesting that ANO7 is a potential PrCa susceptibility gene and that its elevated expression correlates with disease severity and outcome.

AB - Prostate cancer is one of the most common and heritable human cancers. Our aim was to find germline biomarkers that can predict disease outcome. We previously detected predisposing signals at 2q37, the location of the prostate specific ANO7 gene. To investigate, in detail, the associations between the ANO7 gene and PrCa risk and disease aggressiveness, ANO7 was sequenced in castration resistant tumors together with samples from unselected PrCa patients and unaffected males. Two pathogenic variants were discovered and genotyped in 1769 patients and 1711 unaffected males. Expression of ANO7 vs. PrCa aggressiveness was investigated. Different databases along with Swedish and Norwegian cohorts were used for validation. Case–control and aggressive vs. nonaggressive association analyses were performed against risk and/or cancer aggressiveness. The ANO7 mRNA level and patient survival were analyzed using expression data from databases. Variant rs77559646 showed both risk (OR 1.40; p = 0.009, 95% CI 1.09–1.78) and association with aggressive PrCa (Genotype test p = 0.04). It was found to be an eQTL for ANO7 (Linear model p-values for Finnish patients p = 0.009; Camcap prostate tumor p = 2.53E-06; Stockholm prostate tumor cohort p = 1.53E-13). rs148609049 was not associated with risk, but was related to shorter survival (HR 1.56; 95% CI 1.03–2.36). High ANO7 expression was independently linked to poor survival (HR 18.4; 95% CI 1.43–237). ANO7 genotypes correlate with expression and biochemical relapse, suggesting that ANO7 is a potential PrCa susceptibility gene and that its elevated expression correlates with disease severity and outcome.

KW - ANO7

KW - CRPC

KW - expression

KW - prostate cancer

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85053693898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053693898&partnerID=8YFLogxK

U2 - 10.1002/ijc.31746

DO - 10.1002/ijc.31746

M3 - Article

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -